Ethicon Suspends Minimally Invasive Uterine Surgery Equipment

Share on Facebook
Device company Ethicon has suspended sales of its Morcellation Devices, citing Food and Drug Administration concerns that the practice — laparoscopic power morcellation, which is used to remove uterine fibroids — spreads cancerous tissue during fibroid removal, according to a report from the Cincinnati Enquirer.

While Ethicon's devices for the procedure have included a warning about the spread of cancerous cells, it has decided to suspend the devices until such time as the FDA clearly defines the risks associated with morcellation, according to the report.

"At Ethicon, our first priority is to our customers and patients," a company spokesman told the Enquirer.

More Articles on Quality:
5 Tips for Focusing Infection Control Policies
10 Things to Know About Infection Control

ASCA Encourages AHRQ ASC Patient Safety Program Participation

© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

New From Becker's Infection Control & Clinical Quality

Patient safety tool: NPSF's checklist for getting the right diagnosis

Read Now